CSIMarket
 
Aligos Therapeutics Inc   (ALGS)
Other Ticker:  
 
 
Price: $0.9215 $0.05 5.956%
Day's High: $0.97 Week Perf: 4.72 %
Day's Low: $ 0.84 30 Day Perf: 41.77 %
Volume (M): 1,051 52 Wk High: $ 1.38
Volume (M$): $ 969 52 Wk Avg: $0.87
Open: $0.87 52 Wk Low: $0.54



 Market Capitalization (Millions $) 40
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) 16
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) 90
 Capital Exp. (TTM) (Millions $) 0

Aligos Therapeutics Inc
Aligos Therapeutics Inc is a pharmaceutical company focused on developing innovative treatments for viral infections and liver diseases. The company is dedicated to addressing the unmet medical needs in these areas by utilizing cutting-edge science and research. Aligos Therapeutics aims to provide effective and safe therapies to patients around the world by leveraging its expertise in virology and liver biology. The company's mission is to improve the lives of those affected by viral infections and liver diseases through groundbreaking drug development and clinical research.


   Company Address: One Corporate Drive South San Francisco 94080 CA
   Company Phone Number: 466-6059   Stock Exchange / Ticker: NASDAQ ALGS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Aligos Therapeutics Ventures into Phase 2a HERALD Study for Potential MASH Treatment, Provides Hope for Patients with Unmet Medical Needsnnn

Published Mon, Mar 18 2024 12:01 PM UTC

Aligos Therapeutics, a prominent clinical stage biopharmaceutical company, has recently announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). The study aims to address the unmet medical needs in liver and viral diseases and is a significant step for Aligos in developing novel therapeutics...

Aligos Therapeutics Inc

Revised headline: Aligos Therapeutics Inc Shows Strong Progress in Q3 2023 Despite Revenue Decline

Aligos Therapeutics Inc, a biopharmaceutical company specializing in the development of innovative therapies for liver diseases, recently released its financial results for the fiscal third quarter of 2023. Despite facing some challenges, the company demonstrated significant improvements in various aspects of its performance.
In terms of the company's financials, Aligos Therapeutics Inc managed to decrease its loss per share to $-0.41, showing improvement from the previous year's $-0.44 per share loss. Additionally, the company's earnings per share (EPS) improved from $-0.43 in the previous reporting period. These promising figures indicate Aligos Therapeutics Inc's progress in managing its losses and moving towards profitability.

Product Service News

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

Published Fri, Nov 3 2023 8:30 PM UTC


Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data on Emerging HBV Therapies
November 16 Event to feature KOL perspective on Emerging HBV Therapies
In the ever-evolving landscape of hepatitis B virus (HBV) therapies, Aligos Therapeutics has once again taken the lead by organizing a Knowledge-Opinion-Leader (KOL) event. T...

Aligos Therapeutics Inc

Aligos Therapeutics Posts Stellar Revenue Growth, Shrinks Losses Amid Q2 2023 Earnings Season Despite Share Value Dip



Aligos Therapeutics Inc, a biotech company specializing in the development of innovative therapeutics, has recently witnessed a short-term decline in its share value. Over the past 7 days, its shares declined by -4.3%, contributing to a year-to-date performance of -5.32%. However, despite this temporary setback, the company's financial results indicate positive growth and promise for the future.
Revenue Improvement and Earnings Per Share:
Aligos Therapeutics Inc's most recent fiscal period showcased a notable revenue improvement, with revenue surging by 86.461% to $6.89 million. This impressive increase in revenue has played a crucial role in reducing losses from $-0.47 per share to $-0.43 per share, benefitting the company's bottom line. In comparison, in the same reporting period a year earlier, the company had reported revenue of $2.72 million, indicating a significant 152.883% increase. Additionally, the company's earnings per share (EPS) improved from $-0.53 per share, further highlighting its positive financial trajectory.

Aligos Therapeutics Inc

Biotechnology & Pharmaceuticals Company Reports Deficit of $0.53 per Share in Q1 20232.

Aligos Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies to treat liver diseases. In particular, the company is focused on developing therapies for chronic hepatitis B, a potentially life-threatening viral infection that affects around 250 million people worldwide. Hepatitis B can cause liver damage, liver cancer, and even death if left untreated.
Despite the company's focus on a critical disease area, Aligos Therapeutics Inc has struggled to turn a profit. As reported in the first quarter of 2023, the company recorded a cumulative net loss of $-83 million, resulting in a negative return on investment (ROI) of -67.85%. These numbers indicate that for every dollar invested in Aligos Therapeutics Inc, investors lost almost $0.68.






 

Aligos Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com